Matches in Nanopublications for { ?s ?p "[These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP442000.RAApGuBYlP7CoyZ013Y0bfk7HSyZE37bJsb2HtG-BCT2w130_assertion description "[These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP442000.RAApGuBYlP7CoyZ013Y0bfk7HSyZE37bJsb2HtG-BCT2w130_provenance.
- NP442002.RAZjAnvDHu_uw50LNUSJaayVzO-Mt6xGSwgUC2p06WNJs130_assertion description "[These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP442002.RAZjAnvDHu_uw50LNUSJaayVzO-Mt6xGSwgUC2p06WNJs130_provenance.
- assertion description "[These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1159010.RA32NOjKAVrC0JuEzRONE71cT_WqEnpJfmKNEocZ7SUzc130_assertion description "[These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1159010.RA32NOjKAVrC0JuEzRONE71cT_WqEnpJfmKNEocZ7SUzc130_provenance.
- NP1159009.RAHNdebD2Vl_6O2QCpzsciXGHLiQL75ba12i5ygHpptlE130_assertion description "[These data provide treatment options for affected individuals and strongly suggest that investigation of GUCY1A3 and other members of the NO-sGC-cGMP pathway is warranted in both isolated early-onset achalasia and nonsyndromic moyamoya.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1159009.RAHNdebD2Vl_6O2QCpzsciXGHLiQL75ba12i5ygHpptlE130_provenance.